Swiss Biotech – Industry news, events, directory, Swiss Biotech Association

Get the insight

Swiss Biotech Report 2026

How did we fare in 2025?

Our association in facts and figures

In print & digitally

The leading compedium of Swiss Biotech

Become a Member

Loads of reasons to join

Invest in Swiss biotechs

Discover investment and partnering opportunities

Talent meets opportunities

Become part of the thriving community

Create lasting business ties

Connect with the Swiss biotech ecosystem

Total revenues reached a record CHF 7.5 billion in 2025 (CHF 7.2 billion in 2024) with more companies maturing to the commercial stage and a continuously growing demand for specialized CDMO services. Funding increased by 2.1% to CHF 2.6 billion. In a notable shift, investments in privately funded companies achieved a record CHF 1.15 billion – an increase of 38% compared to 2024, and a record 45%
May 5, 2026

We are tracking and escalating fraud campaigns targeting Swiss Biotech Association members and Swiss Biotech Day participants. Multiple fraudulent domains and Gmail accounts have already been identified and reported to their registrars and hosts; several have been taken down, but new ones continue to appear. Please read this alert carefully and share it within your organization.
April 16, 2026

The collaboration brings an advanced preclinical SOD1 gene therapy program, into Institut Charcot's growing ALS pipeline, provides a concrete demonstration of ReMedys Foundation's translational model and strengthens Avrion's focus on preparing AVR-001 for clinical development.
August 27, 2026

DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027 CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in 2027 Cash position of CHF 67.9 million (USD ~84 million) as of June 30, 2026, expected to fund operat
August 25, 2026

Avrion Therapeutics Appoints New Chief Executive Officer and Strengthens Leadership Team to Advance ALS Pipeline. Harald Petry transitions to Chairman of the Board and Chief Scientific Officer; Patrik Richard is appointed Chief Operating Officer; Ravi Sodha joins as Vice President, Business Development
August 24, 2026

Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the company access to non-dilutive funding for the development of its R&D pipeline.
August 14, 2026

Nomination recognizes the company's pioneering META 10 metabolic reprogramming platform and its clinical translation into next-generation cell therapies.
August 13, 2026